Meta-analysis identifies new genetic loci linked to acute myeloid leukemia risk in 4710 cases.

This meta-analysis examined the association between common genetic variants and the risk of acute myeloid leukemia (AML). The study included 4710 AML cases and 12,938 controls, focusing on variants at 1q23.3, 2p23.3, 2q33.3, and 2p21. The analysis aimed to determine if these genetic markers influence AML risk, survival, or clonal hematopoiesis.

The authors identified four new genome-wide significant risk loci. A pan-AML risk locus was found at 2p23.3 (rs4665765) with a P value of 1.35 × 10^-8. Additional loci were identified at 1q23.3 (rs12078864) for AML with deletions of chromosome 5 and/or 7 (P = 7.0 × 10^-10), at 2q33.3 (rs12988876) for cytogenetically complex AML (P = 3.28 × 10^-8), and at 2p21 (rs79918355) for cytogenetically complex AML (P = 1.60 × 10^-9).

Patient survival was significantly associated with the genetic variants (P = 6.09 × 10^-3). The study also assessed the risk of clonal hematopoiesis (CH) and CH of indeterminate potential, though specific effect sizes for these outcomes were not reported in the provided data. No adverse events or tolerability data were available.

The authors did not report funding, conflicts of interest, or specific limitations. Given the observational nature of the genetic data, causal language is avoided. The clinical relevance for routine practice is not explicitly detailed in the source text.